Navigation Links
Inspiration Biopharmaceuticals Presents Data From Hemophilia,Program at International Society On Thrombosis and Haemostasis,(ISTH) Annual Meeting

GENEVA, July 11, 2007 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of preclinical data supporting the development of new, proprietary forms of recombinant Factor IX to treat patients with Hemophilia B. The data were highlighted in an oral presentation and a poster session at the XXIst Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Geneva, Switzerland.

Dougald M. Monroe, Ph.D., Associate Professor, UNC School of Medicine, University of North Carolina at Chapel Hill, gave an oral presentation titled, "Glycosylation of the Activation Peptide of Factor IX Determines Plasma Half Life." Michael Griffith, Ph.D., President and CEO of Inspiration Biopharmaceuticals, presented a poster titled, "N-Glycan Sialylation is Important for In Vivo Recovery of Recombinant Factor IX." According to both presentations, Inspiration has identified structural properties of Factor IX that may improve the half-life and recovery compared to commercially available recombinant Factor IX. The company is currently refining its cGMP manufacturing process to maximize the biological properties of its clinical product based on these studies.

"Inspiration Biopharmaceuticals is seeking to revolutionize the treatment of hemophilia by providing high quality, less costly Factor products. Our ultimate goal is to increase accessibility to prophylactic treatment and improve the quality of life for people suffering from hemophilia," said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. "We are therefore excited about the progress that we have made in advancing our protein manufacturing technology. We look forward to initiating clinical trials this year."

About Recombinant Protein Manufacturing Technology

Inspiration Biopharmaceuticals uses novel patent protected, recombinant protein manufacturing technologies which are demonstrated to s ignificantly increase cell-line productivity. This in turn decreases manufacturing capacity requirements, and significantly lowers the overall production cost for Factor products compared with existing manufacturing processes. Inspiration believes that its technologies will allow introduction of patient friendly, cost-effective products which will provide equal or enhanced potency compared to those currently available.

About Inspiration Biopharmaceuticals

Founded in 2004, Inspiration Biopharmaceuticals is focused on revolutionizing the treatment of hemophilia through production of lower cost versions of existing intravenous recombinant therapies and development of non-invasive applications to enhance prophylactic administration. The Company's first product candidate is to be a less costly intravenous presentation of recombinant Factor IX. The proposed second generation product is a non-injectable recombinant Factor IX, designed specifically for prophylactic therapy.

CONTACT: Alison Arter of Inspiration Biopharmaceuticals,, or Media, Justin Jackson, or Kathy Nugent, orInvestors, Clay Kramer, all of Burns McClellan for InspirationBiopharmaceuticals, +1-212-213-0006 aarter@inspirationbio.com

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
4. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in Israel ... Wound care is $2 5 billion ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of ... Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia for the ...
(Date:1/19/2017)... -- The Global Therapy Partnering Terms and Agreements since ... and agreements entered into by the world,s leading healthcare ... deals by value - Deals listed by company A-Z, ... report provides understanding and access to the partnering deals ... companies. The report provides an analysis of partnering ...
(Date:1/19/2017)... Jan. 18, 2017   Synthetic Biologics, Inc. ... developing therapeutics designed to preserve the microbiome to ... confirmed plans to initiate a Phase 2b/3 adaptive ... of lovastatin lactone designed to reduce methane production ... the gut to treat the underlying cause of ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser ... Cancer Institute. For Betsy, the clinical trial has been life-saving as she has ... worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who ... the creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the ... and at 19 years of age, he joined the Navy and got married right out ...
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers that reminds ... published author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published ... high school and have many different titles,” Gaapf mentions about his different works. “I ...
(Date:1/19/2017)... ... ... Next week after January 20th, the fear for many is that the humane ... of over 30 million. Many interviews with Dr. Carol Francis at the Los Angeles ... suppose to prioritize. Interviews provided below. , Among those present was Senator ...
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital media ... American Heart Association (AHA) to produce a three-part video series that uses humor to ... part of the launch of AHA’s Healthy For Good™ movement, which is designed to ...
Breaking Medicine News(10 mins):